In the journals
Caulfield T, Evans J, McGuire A, McCabe C, Bubela T, et al. (2013) Reflections on the Cost of “Low-Cost” Whole Genome Sequencing: Framing the Health Policy Debate. PLoS Biol 11(11): e1001699. doi:10.1371/journal.pbio.1001699
Given the interest and significant investment in genomics, this seems an ideal time to consider what the evidence tells us about potential benefits and harms, particularly in the context of health care policy.
In the news
The personal genotyping service by 23andMe got smacked down by the U.S. FDA; but it probably won’t slow down the rush to consumer genomics.